Publications scientifiques sur le VIH
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
2019
Lancet HIV.
Stanley TL, Fourman LT, Feldpausch M, et al.
6(12):e821-e830.
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
2018
N Engl J Med.
Emu B, Fessel J, Schrader S, et al.
379(7):645-654.
Outcomes of patients not achieving primary endpoint from an ibalizumab phase 3 trial.
2018
J Int AIDS Soc.
DeJesus E, Emu B, Weinheimer S, et al.
21(suppl 8):e25187. Proceedings of HIV Glasgow, 2018.
Outcomes of patients not achieving primary endpoint from an ibalizumab phase 3 trial.
2018
DeJesus E, Emu B, Weinheimer S, et al.
Poster #P064 presented at: HIV Glasgow; October 28-31 2018; Glasgow, UK.
Analysis of patients completing the ibalizumab phase 3 trial and expanded access program [abstract].
2018
J Int AIDS Soc.
Emu B, Weinheimer S, Cohen Z, Lewis S.
21(Suppl 8):e25187. Proceedings of HIV Glasgow, 2018.